

PI Major Mutations:

PI Accessory Mutations:

PR Other Mutations:

M46I100%
seen:23,258

•

I54V100%
seen:21,992

•

V82A99%
seen:12,034

L10F99%
seen:24,258

•

K43T99%
seen:24,752

•

T74P100%
seen:23,258

I13V99%
seen:1,092

•

G16A99%
seen:7,392

•

K20R99%
seen:7,312

•

L33I100%
seen:17,202

•

E35D100%
seen:17,362

•

M36I99%
seen:17,362

•

R41K99%
seen:24,672

•

K35R100%
seen:23,262

•

R37K100%
seen:20,442

•

L63V100%
seen:20,762

•

H69K99%
seen:20,202

•

L89M99%
seen:11,812

Protease Inhibitors	
atazanavir/r (ATV/r)	High-Level Resistance
darunavir/r (DRV/r)	Potential Low-Level Resistance
fosamprenavir/r (FPV/r)	High-Level Resistance
indinavir/r (IDV/r)	High-Level Resistance
lopinavir/r (LPV/r)	High-Level Resistance
nelfinavir (NFV)	High-Level Resistance
saquinavir/r (SQV/r)	High-Level Resistance
tipranavir/r (TPV/r)	High-Level Resistance

PR comments

Major

- M46I/L are relatively non-polymorphic PI-selected mutations. In combination with other PI-resistance mutations, they are associated with reduced susceptibility to each of the PIs except DRV.
- I54V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.
- V82A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.

Accessory

- L10F is a common non-polymorphic, PI-selected accessory mutation associated with reduced in vitro susceptibility to LPV and DRV.
- K43T is a nonpolymorphic accessory mutation selected by ATV and LPV. Its phenotypic effect on currently used PIs is uncertain.
- T74P is a nonpolymorphic PI-selected accessory mutation that occurs primarily in viruses from persons who have received multiple PIs. In combination with other mutations, it is associated with reduced susceptibility to ATV and DRV.

Other

- K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.
- L33I/V are minimally polymorphic mutations that do not appear to be selected by PIs or to reduce their susceptibility.

Drug resistance mutation scores of PI:

Download CSV

Rule	ATV/r	DRV/r	FPV/r	IDV/r	LPV/r	NFV	SQV/r	TPV/r
M46I	10	0	10	10	10	30	10	5
M46I + V82A	10	0	10	10	10	10	10	0
I54V	15	0	10	15	15	20	15	20
I54V + V82A	10	0	10	10	10	10	10	0
T74P	10	5	10	10	5	20	10	25
V82A	15	0	15	30	30	30	15	0
L10F	0	5	15	10	5	15	0	0
K43T	0	0	0	0	0	10	0	10
Total	70	10	80	95	85	145	70	60

NRTI Mutations:

NNRTI Mutations:

RT Other Mutations:

M41L99%
seen:11,776

•

E44D100%
seen:12,726

•

D67N99%
seen:12,182

•

M184V99%
seen:12,262

•

L210W99%
seen:12,712

•

T215Y99%
seen:12,092

•

K219N99%
seen:1,182

A98G100%
seen:12,362

•

K101H100%
seen:9,776

•

V108I99%
seen:10,672

•

G190A100%
seen:9,622

•

H221HY99%
seen:12,712

K20R99%
seen:11,182

•

V35T100%
seen:12,262

•

T39R99%
seen:12,032

•

K43E100%
seen:12,402

•

V60I99%
seen:12,712

•

V118I100%
seen:12,032

•

K122E100%
seen:12,262

•

D123S99%
seen:11,032

•

K173A100%
seen:12,632

•

D177E99%
seen:12,032

•

I178F100%
seen:12,032

•

E203K99%
seen:12,032

•

Q207D99%
seen:12,712

•

H208Y99%
seen:1,722

•

R211K99%
seen:12,712

Nucleoside Reverse Transcriptase Inhibitors		Non-nucleoside Reverse Transcriptase Inhibitors	
abacavir (ABC)	High-Level Resistance	doravirine (DOR)	Intermediate Resistance
zidovudine (AZT)	High-Level Resistance	efavirenz (EFV)	High-Level Resistance
stavudine (D4T)	High-Level Resistance	etravirine (ETR)	Intermediate Resistance
didanosine (DDI)	High-Level Resistance	nevirapine (NVP)	High-Level Resistance
emtricitabine (FTC)	High-Level Resistance	rilpivirine (RPV)	Intermediate Resistance
lamivudine (3TC)	High-Level Resistance		
tenofovir (TDF)	High-Level Resistance		

RT comments

NRTI

- **M41L** is a TAM that usually occurs with T215Y. In combination, **M41L** plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddi, ABC and TDF susceptibility.
- **E44D** is a relatively non-polymorphic accessory mutation; E44A is a nonpolymorphic accessory mutation. Each usually occurs with multiple TAMs.
- **D67N** is a non-polymorphic TAM associated with low-level resistance to AZT.
- **M184V/I** cause high-level in vitro resistance to 3TC and FTC and low/intermediate resistance to ABC (3-fold reduced susceptibility). **M184V/I** are not contraindications to continued treatment with 3TC or FTC because they increase susceptibility to AZT and TDF and are associated with clinically significant reductions in HIV-1 replication.
- **L210W** is a TAM that usually occurs in combination with M41L and T215Y. The combination of M41, **L210W** and T215Y causes high-level resistance to AZT and intermediate resistance to ABC and TDF.
- **T215Y/F** are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.
- **K219E/Q/N/R** are accessory TAMs that usually occur in combination with multiple other TAMs.

NNRTI

- **A98G** is a non-polymorphic accessory mutation associated with low-level reduced susceptibility to each of the NNRTIs.
- **K101H** is a non-polymorphic accessory mutation selected by NVP, EFV and ETR. When present with other NNRTI-resistance mutations, it contributes reduces susceptibility to these NNRTIs.
- **V108I** is a relatively non-polymorphic accessory mutation selected in vitro and/or in vivo with each of the NNRTIs. It appears to contribute to reduced susceptibility to most NNRTIs only in combination with other NNRTI-resistance mutations.
- **G190A** is a non-polymorphic mutation that causes high-level resistance to NVP and intermediate resistance to EFV. It does not significantly reduce susceptibility to RPV, ETR, or DOR.
- **H221Y** is a non-polymorphic accessory mutation selected primarily by NVP, RPV, and DOR. It frequently occurs in combination with Y181C.

Other

- **V118I** is a polymorphic accessory NRTI-resistance mutation that often occurs in combination with multiple TAMs.
- This virus is predicted to have intermediate-level reduced susceptibility to **RPV**. The use of the combination of CAB/**RPV** should be considered to be contraindicated.

Mutation scoring: RT

HIVDB 9.5.1 (2023-11-05)

Drug resistance mutation scores of NRTI:

Download CSV

Rule	ABC ↕	AZT ↕	D4T ↕	DDI ↕	FTC ↕	3TC ↕	TDF ↕
<u>M41L</u>	5	15	15	10	0	0	5
<u>M41L + E44D + L210W + T215Y</u>	5	5	5	5	0	0	5
<u>M41L + D67N + T215Y</u>	5	5	5	5	0	0	5
<u>M41L + M184V + T215Y</u>	10	0	0	0	0	0	0
<u>M41L + L210W</u>	10	10	10	10	0	0	10
<u>M41L + L210W + T215Y</u>	10	0	0	0	15	15	10
<u>M41L + T215Y</u>	10	10	10	10	5	5	10
<u>D67N</u>	5	15	15	5	0	0	5
<u>D67N + T215Y + K219N</u>	5	5	5	5	0	0	5
<u>M184V</u>	15	-10	-10	10	60	60	-10
<u>L210W</u>	5	15	15	10	0	0	5
<u>L210W + T215Y</u>	10	10	10	10	0	0	10
<u>T215Y</u>	10	60	40	15	0	0	10
<u>K219N</u>	5	10	10	5	0	0	5
Total	110	150	130	100	80	80	75

Drug resistance mutation scores of NNRTI:

Download CSV

Rule	DOR ↕	EFV ↕	ETR ↕	NVP ↕	RPV ↕
<u>A98G</u>	15	15	10	30	15
<u>V108I</u>	10	10	0	15	0
<u>H221HY</u>	10	10	10	15	15
<u>K101H</u>	0	10	10	15	10
<u>G190A</u>	0	45	10	60	15
Total	35	90	40	135	55